Hone Health Review
✓ Updated July 2026
By the TelehealthIndex Editorial Team · How we score Fair · #6 in Men's Health (ED & TRT)
By the TelehealthIndex Editorial Team · Advertising Disclosure: TelehealthIndex is reader-supported. If you sign up with a
provider through links on this page, we may earn a commission at no extra cost to you.
Commissions never influence our scores or rankings — several of our top-rated providers pay
us nothing. How we score → · Full disclosure →
53.7/100
Hone Health score
Fair · #6 in Men's Health (ED & TRT) · Data as of July 2026
Clinical credibilityWeak
Regulatory & safety recordMinor deductions
Transparency & trustMixed
Access & coverageWeak
Customer experienceStrong
Value & pricingWeak
Pillar ratings are qualitative summaries of our internal rubric; we do not publish the
point weights. Read the full methodology →
TelehealthIndex scores and rankings are editorial opinions resulting from our selection, weighting, and interpretation of the factors described in our methodology.
What it is
Lab-first TRT/hormone optimization; $65 50+ biomarker panel; largest TRT review base; LegitScript-certified.
Strengths
- Strong consumer-review signals
Considerations
- Compounded enclomiphene (not FDA-approved) and third-party-reported peptide catalog
- Named in KFF/CBS investigation of TRT telehealth marketing tactics
- DEA telehealth flexibility for testosterone (Sch. III) expires Dec 31, 2026 - category-wide risk
Note: this provider offers compounded medications for one or more services.
Compounded medications are not FDA-approved.
Founded2020
OwnershipPrivate (VC-backed)
AvailabilityNot disclosed
InsuranceNo
Money-back guaranteeNot advertised
Pricing$65 initial labs+consult; $25/mo membership + meds (T from $28/mo)
Visit Hone Health
We may earn a commission — disclosure.
Alternatives to consider
Data as of July 19, 2026. Scores are editorial opinions reflecting documented business practices, transparency, pricing, access, and nonclinical consumer-service factors — not clinical quality or outcomes. Found an error? Report it →